Lifemd, Inc. · NASDAQ:LFMD
Lifemd — Investor Presentation (November 2023)
22 slides from Lifemd's investor presentation, November 2023
Slide 1: Investor Presentation
Investor Presentation November 2023 NASDAQ: LFMD
Slide 2: Important cautions regarding forward-looking statements
2 Important cautions regarding forward-looking statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Priva
Slide 3: Building the leading platform for comprehensive virtual healthcare
3 Building the leading platform for comprehensive virtual healthcare 800,000 Virtual Consults Conducted End-to-end, compliance-first platform for direct-to- consumer virtual primary care Early-mover advantage and partnership strategy create a 207,000 Active Patients deep competitive moat Affiliated
Slide 4: Investment highlights
4 Investment highlights Proven ability to operate at scale within large and growing addressable markets thanks to robust infrastructure Differentiated, end-to-end technology platform and affiliated medical group supporting complex virtual primary care needs of ~750 new patients per day Significant g
Slide 5: Telehealth can solve many of the biggest problems facing the U.S. healthcare system
5 Telehealth can solve many of the biggest problems facing the U.S. healthcare system Need Solution 1/3 of Americans don’t have a primary care doctor, At LifeMD, the median time from scheduling to the Timeliness and the average wait time to see a family doctor is first provider appointment is only 2
Slide 6: A $170 billion total addressable market in the U.S.
6 A $170 billion total addressable market in the U.S. LifeMD’s virtual care platform is addressing unmet needs in primary care and specialized healthcare. Male and Female Sexual Health Insomnia U.S. Primary Care Market Weight Management Integrative Health & Wellness $170B Diabetes Management Hormone
Slide 7: LifeMD has built an end-to-end platform for comprehensive virtual healthcare
7 LifeMD has built an end-to-end platform for comprehensive virtual healthcare Patient Acquisition Diagnostics Internal creative, online/offline media Integrations with Quest & LabCorp buying, SEO, and CRM platform and in-home collection Business Intelligence Telehealth Data & analytics platform to
Slide 8: Technology designed to provide best-in-class experience and care for all stakeholders
8 Technology designed to provide Best-in-class experience and care for all stakeholders For Patients For Providers For Partners For Industry Patients benefit from an intuitive Streamlined workflow optimization Flexible partnerships with unique Life sciences companies who partner virtual care platfor
Slide 9: Our affiliated medical group, staffed by full-time providers, is central to our success
9 Our affiliated medical group, staffed by full-time providers, is central to our success 99% 800K 200+ 4.9/5 Of consults start on Consults completed Different conditions Average physician time* LifeMD treats rating Dr. Gupta 98% 50 LifeMD Affiliated Provider “I love what I do because I Patients sat
Slide 10: Our success is driven by three core pillars
10 Our success is driven by three core pillars DTC Telemedicine Virtual Primary Care B2B Solutions Subscription-based treatment Services include primary care, Digital front-door strategies for + Rx Offerings urgent care, and chronic healthcare product companies condition management Established, whol
Slide 11: Our track record of strategic focus and growth
11 Our track record of strategic focus and growth JUNE JUNE NOVEMBER APRIL Acquired cloud – Commenced tech build Launched Launched GLP-1 based telehealth for LifeMD Virtual Primary VPC Platform offering on VPC technology platform Care (VPC) platform platform FEBRUARY AUGUST Q3 2023 DECEMBER Changed
Slide 12: Clear strategy focused on scaling high-value revenue streams
12 Clear strategy focused on scaling high-value revenue streams Key Priorities Goals Virtual Primary Care Continue to scale weight management/GLP-1 offering High Value Revenue Streams With Long-Term Brand Equity Launch cardiovascular health and hormone therapy offerings Launch commercial health insu
Slide 13: WorkSimpli Software is rapidly growing and highly profitable
13 WorkSimpli Software is rapidly growing and highly profitable Rapidly growing, global provider of Workplace and document Software-as-a-Service offerings to consumers and small businesses specializing in the pdf, resume/ HR, digital signature and forms markets Over 170,000 subscribers with platform
Slide 14: Our management team has deep experience leading innovative healthcare organizations
14 Our management team has deep experience leading innovative healthcare organizations Justin Schreiber Marc Benathen Brad Roberts Stefan Galluppi Chief Executive Chief Financial Officer Chief Operating Officer Chief Innovation Officer & Chairman Officer Jessica Friedeman Eric Yecies Dennis Wijnker
Slide 15: Our businesses have experienced rapid, consecutive YoY growth
15 $148-$149M Our businesses have experienced rapid, consecutive YoY Growth $55M $119M $148M - $149M 2023E Revenue Forecast $93M $36M $25M 24% - 25% YoY Estimated Revenue $94M Growth in ‘23 $83M $37M $68M $7M 800K+ $13M $2M $30M Patients & Customers $11M To-Date 2019A 2020A 2021A 2022A 2023E 198% 14
Slide 16: Rapid growth in profitability after achieving adjusted EBITDA profit in Q4 '22
16 Rapid growth in profitability after achieving adjusted EBITDA profit in Q4 ‘22 Annual consolidated adjusted EBITDA ($ millions) $10-$11M 2023E $(15)M ($38)M 2022A 2021A Note: Consolidated adjusted EBITDA includes Telehealth and WorkSimpli results.
Slide 17: Rapidly expanding gross margins and increasing leverage on marketing spend
17 Rapidly expanding gross margins and increasing leverage on marketing spend driving continued growth in profitability Consolidated Gross Margin % Marketing Expenses as % of Net Revenue 90% 125% 89% 38 100% Net Revenue ($ Millions) 88% 35 51% 87% 72% 62% 32 75% 50% 54% 86% 55% 29 85% 50% 84% 26 25%
Slide 18: Full year 2023 guidance reflecting substantial profitability growth
18 Full year 2023 guidance reflecting substantial profitability growth FY 2023 GUIDANCE FY 2022 ACTUAL DELTA Consolidated Net $148 - $149 million $119 million +24 - 25% Revenue Gross Margin % 87% 84% +300 bps Consolidated Adj. $10-$11 million $(15) million +$25 – $26 million EBITDA Free Cash Flow Br
Slide 19: In summary
19 In summary Significant presence within established and growing addressable markets Proprietary technology platform differentiated by leading 50-state, affiliated physician network High margin products/services generating 85%+ consolidated gross margins Powerful telehealth infrastructure enabling
Slide 20: Appendix
20 Appendix LifemD"
Slide 21: Reconciliation of GAAP Net Loss to Adjusted EBITDA
Reconciliation of GAAP Net Loss to Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net loss attributable to common shareholders $ (5,467,761) $ (8,058,236) $ (17,762,342) $ (35,929,997) Interest expense (excluding amo
Slide 22: Company Contact
Company Contact Marc Benathen [email protected] Media Contact [email protected]